Cannabis Law Report

DECEMBER 14, 2021

(“IGC” or the “Company”) today announced positive primary endpoint data for its Phase 1 clinical trial for IGC-AD1, which is a proprietary cannabinoid-based investigational new drug candidate for patients who have Alzheimer’s disease. The trial was conducted as a multiple ascending dose (MAD) study. The average age was 80.9

Clinical Trials 52

Clinical Trials Safety Data Patients 52

Cannabis Law Report

OCTOBER 6, 2021

(NASDAQ: FLGC) (“Flora” or the “Company”), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, is pleased to announce that it has signed an agreement to begin scientific clinical trials globally. Forward-looking statements are only predictions. Investor Relations: Evan Veryard.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

Puff Puff Post

NOVEMBER 5, 2019

5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. VANCOUVER, Nov.

Clinical Trials 40

Clinical Trials Pharmaceutical Cannabinoids Data 40

Puff Puff Post

MARCH 10, 2020

InMed and CHDR are currently preparing the Clinical Trial Application for a second Phase 1 clinical trial (755-102-HV), planned to begin in the second quarter of 2020, which will examine the local safety of INM-755 on small areas of wounded skin in healthy volunteers.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Cannabis Law Report

SEPTEMBER 13, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. in the blood. 3 Nature Aging | VOL 1 | July 2021 | p. 616–623.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

Cannabis Law Report

JANUARY 7, 2020

With our recent event in Cape Town, we have now brought CannaTech to every continent and helped build the cannabis footprint across the world. PsychedeliTech is our newest “Incubaby” designed to create a global ecosystem to accelerate psychedelic innovation by investing in research, education and clinical trials.

Events 59

Events Clinical Trials Decriminalization Education 59

MMJ Recs

JULY 30, 2024

Post-Traumatic Stress Disorder (PTSD) is a multifaceted mental health condition triggered by experiencing or witnessing traumatic events, persistently manifesting in symptoms like flashbacks, severe anxiety, and disrupted sleep. Looking ahead, the future of medical cannabis in PTSD treatment hinges on overcoming these challenges.

Therapy 116

Therapy Treatment Clinical Trials Sleep 116

TheAnswerPage

MARCH 11, 2022

In the clinical trials evaluating a purified CBD product (Epidiolex) in epilepsy patients, side effects including sedation, decreased appetite, diarrhea, sleep disturbance, infections, pneumonia, viral infections and weight loss were reported. ” Kirkland AE, Fadus MC et al. Psych Resear. 308 (2022). See the Answer.

Clinical Trials 52

Clinical Trials Epilepsy Events Sleep 52

Veriheal

JUNE 30, 2023

For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial. The 13 individuals were chosen because of their reported improvements in negative drinking behavior following the clinical trial.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

TheAnswerPage

NOVEMBER 29, 2021

What serious adverse events have been noted in psilocybin clinical trials? The serious adverse events (AE) reported in the psilocybin clinical trial conducted by Compass Pathways occurred in 12 of the 233 patients and included suicidal behavior, suicidal ideation, and intentional self-injury.

Clinical Trials 52

Clinical Trials Events Patients 52

Veriheal

JUNE 29, 2022

While 233 participants might sound low, it is still the largest number of humans to participate in a psilocybin-based clinical trial. Adverse Events : This finding category refers to suicidal ideation and intentional self-injury, which were seen in all of the treatment groups.

Clinical Trials 104

Clinical Trials Blood Pressure Treatment Therapy 104

Cannabis Law Report

AUGUST 17, 2021

Ganaxolone was generally well-tolerated with somnolence reported as the most common adverse event, consistent with previous trials; in addition, one treatment-related serious adverse event of seizure was reported in the trial. percent in patients on concomitant everolimus and 25.0 Conference Call and Webcast Details.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

NOVEMBER 19, 2021

“These additional patent filings are key as PsyBio moves towards the initiation of appropriately approved safety and efficacy clinical trials for our selected compounds within the production and manufacturing arena, for the Company as well as for our investors.”

Clinical Trials 52

Clinical Trials Research and Development Events Safety 52

TheAnswerPage

FEBRUARY 23, 2022

Some clinical studies have evaluated the safety and efficacy of cannabinoid-based medicines for the treatment of autism spectrum disorder (ASD). Some of these studies have shown positive results, but adverse events were also noted. Fletcher S.

Clinical Trials 52

Clinical Trials Events Therapy Sleep 52

Cannabis Law Report

AUGUST 10, 2021

This acquisition is focused on becoming the first and only company solving the puzzle of chronic pain with MDMA-based medicines utilizing clinical trials for the purposes of novel drug development. These statements relate to future events or future performance. from 2020 to 2030 and generate revenue of $151.7 billion in 2030.

Chronic Pain 105

Chronic Pain Clinical Trials Research and Development Events 105

Cannabis Law Report

SEPTEMBER 9, 2021

Investors may register for the conference at the event website. The live and archived webcast will be available for 90 days after the event. Supera-CBD is being developed to address anxiety, chronic pain, addiction, and seizures, and is on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain.

Pharmaceutical 97

Pharmaceutical Clinical Trials Chronic Pain Epilepsy 97

Cannabis Law Report

DECEMBER 15, 2021

A number of clinical trials have been investigating the potential of psychedelics in mental health treatment. “I agree with the committee that the preliminary findings from clinical trials — although still in early phases — evaluated by the panel are promising,” the decision’s author said.

Clinical Trials 52

Clinical Trials Conditions Supply Chain Environment 52

Cannabis Law Report

JANUARY 27, 2022

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for FXS have been in the early and midphases of development, with 77% of trials in Phase I-II, and only 23% in Phase III-IV. The US has a substantial lead in the number of FXS clinical trials globally. Premutation.

Clinical Trials 52

Clinical Trials Therapy Cannabinoids Topical 52

Cannabis Law Report

JULY 8, 2021

These statements relate to future events or future performance. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Treatment 98

Treatment Clinical Trials CBD Patients 98

NORML

OCTOBER 21, 2019

The agency in 2016 first announced its intent to license private entities to grow cannabis for FDA-approved clinical trials. The Court’s order permits petitioners to return to the Court of Appeals “in the event” that DEA engages in “significant delays” in the future.

DEA 103

DEA Cultivation Clinical Trials Policy 103

Cannabis Law Report

JUNE 17, 2021

Brains is one of a few companies in the world producing CBD as an API for pharmaceutical applications, research, development, and clinical trials. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The post Brains Bioceutical Corp. completes a USD $31.9

Pharmaceutical 105

Pharmaceutical Clinical Trials Research and Development Events 105

Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

The Cannigma

MARCH 25, 2021

It is also crucial so that the correct data is collected in order to inform further research and clinical trials that are necessary for cannabis medicines to reach the UK National Health Service. The idea behind the MDT series is to place the unfamiliar cannabis medicines into a familiar case discussion format.

Patients 145

Patients Clinical Trials Medicine Events 145

Cannabis Law Report

DECEMBER 8, 2021

Charles River Laboratories, a renowned CRO engaged by Virpax to perform Food and Drug Administration (FDA) required pre-clinical studies, has completed a single dose pharmacokinetic study of dermal administration of Epoladerm in minipigs as part of the required Investigational New Drug Application (“IND”) enabling trials.

Clinical Trials 52

Clinical Trials Chronic Pain Pharmaceutical Topical 52

Cannabis Law Report

MARCH 12, 2020

North America and Europe are home to 142 active, or soon-to-be active, clinical trials focused on the therapeutic potential of psychedelic substances. Unsurprisingly the event follows in June. Some psychedelics are already commonly used as therapeutic medicines, with others recently being awarded ‘breakthrough therapy’ status.

Medicine 59

Medicine Clinical Trials Therapy Events 59

Veriheal

MAY 3, 2022

Clinical Trial Sample Size. The trial was conducted with just 186 participants, which is far too small of a sample size to provide findings generalizable to the larger population. a necessary question to address as medical marijuana becomes more accessible.

Research and Development 98

Research and Development Clinical Trials Consumption Patients 98

Cannabis Law Report

NOVEMBER 18, 2021

Nadav Kidron, Oramed CEO and Oravax Chairman, and Rodrigo Herrera, Genomma Lab Chairman, will hold a joint press event today, Thursday, November 18, 2021 at 11:00 am EST. The live press event will be available via Zoom. Oravax is also preparing to commence clinical trials in Israel.”. 19 vaccine candidate in Mexico.

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Chronic Pain 52

Cannabis Law Report

SEPTEMBER 22, 2021

Accelerated timelines to clinical trials and expansion of drug development pipeline. Phase 1 clinical trials are scheduled for Q3 2022 with Phase 2 trials expected in Q2 2023. Exclusive licensing agreement with leading global cannabis company (“Canopy Growth”). the CBD, CBG or THC compounds).

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Cannabinoids 52

Cannabis Law Report

AUGUST 25, 2021

“Lucid has successfully developed a strong pipeline of novel therapeutic compounds — supported by IP in order to advance to future clinical trials — and we are confident that the experience the Lucid leadership team brings will allow us to immediately start the process towards clinical trials to further advance these promising therapies.

Clinical Trials 111

Clinical Trials Research and Development Therapy Conditions 111

Cannabis Law Report

AUGUST 12, 2021

Phase IIb clinical trial of COMP360 psilocybin therapy for TRD close to completion. Except as required by law, COMPASS disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise.

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Cannabis Law Report

NOVEMBER 12, 2021

Completed manufacturing of ANEB-001 capsules for upcoming Phase 2 clinical trial. On track to commence Phase 2 proof-of-concept clinical trial with ANEB-001 for the treatment of acute cannabinoid intoxication by year-end. The founding co-chairs are Andrew Monte, M.D., and Arjun Chanmugam, M.D.,

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Research and Development 52

Cannabis Law Report

OCTOBER 5, 2021

Investors can register for the event here and view the live presentation here. is a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction. Management will deliver a company presentation on October 15 th at 3:25 p.m.

Pharmaceutical 40

Pharmaceutical Clinical Trials Cannabinoids Events 40

Cannabis Law Report

AUGUST 2, 2021

(OTCQB: SPRCY ) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced positive top-line results for its proprietary compound, SCI-160 in a controlled pre-clinical trial on neuropathic and post-operative pain. Logo – [link]. SOURCE SciSparc Ltd.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

JUNE 14, 2022

There are multiple clinical centers doing research with psychedelics in Europe and, inevitably, regulatory approvals in Europe will follow. The partnership will be officially launched at the virtual event: Preparing Europe for Novel Psychedelic-Assisted Therapies taking place on 23rd June, 14:00 – 16:00 CEST.

Access 52

Access Therapy Clinical Trials Treatment 52

Cannabis Law Report

JULY 27, 2021

The longitudinal study showed that individuals who used artisanal cannabidiol (CBD) products reported better quality of life, lower psychiatric symptom severity and fewer medication-related adverse events compared with those not using CBD. This study represents a refreshing collaboration of scientists, clinicians, patients and advocates.

Data 105

Data Epilepsy Research and Development Clinical Trials 105

Cannabis Law Report

FEBRUARY 2, 2022

– Flora seeks approval to take their patent-pending, cannabinoid-based product through clinical trials under an EUA from INVIMA (Colombian FDA). Dr. Manalo-Morgan has spent the last 5 years researching cannabis and has specialized in the formulation of cannabinoid products for clinical trials.

Cannabinoids 52

Cannabinoids Clinical Trials Events Cultivation 52

The Joint Blog

APRIL 21, 2020

This is according to a study published in the Journal of Clinical Medicine Research and epublished by the U.S. For the study researchers with the Nordic Cannabis Research Institute in Denmark reviewed 25 clinical trials assessing the safety and efficacy of CBD in various populations. National Institute of Health.

Clinical Trials 52

Clinical Trials CBD Safety Patients 52